Author

Ryan Hiltenbrand

St. Jude Children's Research HospitalORCID 0000-0002-9267-9844Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Alex KentsisiD· 1 shared Ali KhalighifariD· 1 shared Aurelie ClaquiniD· 1 shared Bappaditya ChandraiD· 1 shared Benjamin A. GarciaiD· 1 shared Bright ArthuriD· 1 shared Chandra Sekhar Reddy ChilamakuriiD· 1 shared Charles Grenfell MullighaniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex KentsisORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MOZ and HBO1 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia

Nicole Lynn Michmerhuizen, Emily Heikamp, Ilaria Iacobucci, Masayuki Umeda, Bright Arthur, Vibhor Mishra, Chun Shik Park, Danika Di Giacomo, Ryan Hiltenbrand, Qingsong Gao, Sandi Radko-Juettner, Josi Lott, Cynthia Martucci, Varsha Subramanyam, Charlie Hatton, , Charles Grenfell Mullighan

This study identifies MOZ and HBO1 as molecular dependencies in NUP98-rearranged AML, showing their inhibition reduces leukemic burden and synergizes with Menin inhibitors.

Cancer Discovery · Jun 19, 2025Peer-reviewedCancer Biology